950192-18-4

Upstream product

• 477585-43-6 methyl 2-amino-2-(tetrahydro-2H-pyran-4-yl)acetate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 894789-28-7 (S)-N-Cbz-pyranyl glycine methyl ester 
• 871261-11-9 (R)-N-Cbz-pyranylglycine methyl ester 
• 1035279-38-9 C₃₃H₄₃N₅O₅ 
• 1035278-84-2 C₂₈H₃₅N₅O₃ 
• 368866-32-4 (S)-pyranylglycine methyl ester 

Relevant academic research and scientific papers

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X1, X2, R1, R2, R3, R4/sub

AZAINDOLE INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and R9 are as described herein.

IMIDAZOPYRIDINE INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3', R4, R4', R5, R6, R6' and n are as described herein.

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1 - M - U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3', R4, R4' and R5, are as described herein.

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and n are as described herein.